PARIS, May 27 (Reuters) - Sanofi and
GlaxoSmithKline said on Thursday they were launching
Phase III trial, the late-stage before submitting approval, for
their experimental COVID-19 vaccine.
Pending positive phase III outcome, the vaccine could be
approved in the fourth quarter 2021 after having initially been
targeted for the first half of this year before a setback.
Sanofi and GSK last December were forced to restart their
trial when the vaccine showed a low immune response in older
adults as a result of a weak antigen formulation.
(Reporting by Dominique Vidalon, Editing by Benoit Van
Overstraeten)
Glaxosmithkline (GSK)
